Vir Biotechnology reports positive hepatitis delta trial data

Vir Biotechnology Inc. (NASDAQ: VIR) reported updated results from its Phase 2 SOLSTICE trial showing that 88% of chronic hepatitis delta participants achieved undetectable virus levels after 96 weeks of combination treatment with tobevibart and elebsiran.

The combination therapy demonstrated superior viral suppression compared to antibody treatment alone. At week 96, 88% of participants receiving the combination achieved undetectable hepatitis delta virus RNA, compared to 46% of those receiving tobevibart monotherapy.

The company reported no grade 3 or higher treatment-related adverse events in the combination treatment group, with side effects described as generally mild to moderate and temporary.

Vir Biotechnology's registrational ECLIPSE program for chronic hepatitis delta continues, with ECLIPSE 1 and ECLIPSE 3 trials fully enrolled. The company expects topline data from ECLIPSE 1 in the fourth quarter of 2026, with ECLIPSE 2 and ECLIPSE 3 results anticipated in the first quarter of 2027.

The company will present Phase 1 safety and efficacy data for VIR-5500, a prostate cancer treatment, at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in February. VIR-5500 targets PSMA and uses the company's PRO-XTEN dual-masked T-cell engager technology.

Vir Biotechnology reported approximately $781 million in cash, cash equivalents and investments as of December 31, 2025. The company expects this funding to support operations through the fourth quarter of 2027, aided by benefits from a licensing agreement with Norgine for European, Australian and New Zealand commercial rights to the hepatitis delta combination therapy.

The information is based on a company press release statement.

You May Also Be Interested In